We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 11, 2019

Pembrolizumab vs Chemotherapy for Previously Untreated PD-L1–Expressing, Locally Advanced or Metastatic NSCLC

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial
Lancet 2019 Apr 04;[EPub Ahead of Print], TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, V Srimuninnimit, KK Laktionov, I Bondarenko, K Kubota, GM Lubiniecki, J Zhang, D Kush, G Lopes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading